At Lineage Cell Therapeutics, CEO Brian Culley has been working for many years on allogeneic cell therapies across a range of ...
Positive RG6501 (OpRegen ®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for ...
As we conclude a successful 2025, I want to extend my appreciation for your continued support of Lineage Cell Therapeutics and our mission to pioneer the emerging field of allogeneic cell therapy. I ...
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2025 Earnings Call Transcript August 12, 2025 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations ...
Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...
The global stem cell market is estimated at $15.10 billion in 2024 and is projected to nearly double to $28.89 billion by 2030, growing at a compound annual growth rate of 11.4 percent. This growth is ...
New python toolkit automates single-cell lineage tracing, accelerates tumor drug resistance analysis
Researchers at Tsinghua University have released a novel Python toolkit, scLT-kit, which automates the processing and analysis of single-cell lineage tracing data, delivering clear insights into how ...
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
Welcome to the Lineage Cell Therapeutics First Quarter 2025 Conference Call. At this time, all participants are in a listen only mode. An audio webcast of this call is available on the Investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results